January 2026 in “Journal of Education Health and Sport” This review assesses whether using letrozole alongside physical activity and nutrition is clinically beneficial for enhancing ovulation outcomes in women with PCOS-related infertility, but it doesn't report specific results from the evaluation.
This review found that metformin improves insulin resistance, hormone levels, and menstrual regularity in non-pregnant women with PCOS, but is less effective for weight loss and ovulation induction.
5 citations
,
December 2024 in “Pharmaceutics” This review discusses the potential of using nanomaterial-based drug delivery systems to improve the treatment of polycystic ovary syndrome but reports no new clinical results, highlighting future research directions.
8 citations
,
August 2023 in “The Journal of Clinical Endocrinology and Metabolism” This study provided updated international guidelines for assessing and managing polycystic ovary syndrome, emphasizing evidence-based recommendations and acknowledging the low to moderate quality of existing evidence.
6 citations
,
August 2023 in “European journal of endocrinology” This review discusses the 2023 International Guideline for PCOS assessment and management, highlighting updated evidence-based recommendations and practice points aimed at improving care and health outcomes, but notes that research quality remains generally low to moderate.
36 citations
,
October 2021 in “Frontiers in Endocrinology” This study highlights the importance of understanding the roles of hyperandrogenemia and insulin resistance in the development and progression of PCOS, emphasizing further research to clarify their mutual influence.
58 citations
,
November 2020 in “International Journal of Molecular Sciences” This review discusses the relationship between SHBG, NAFLD, and PCOS and reports no new clinical results; the authors highlight low hepatic SHBG production as potentially significant in PCOS pathogenesis.
1265 citations
,
October 2013 in “The Journal of Clinical Endocrinology and Metabolism” This guideline from the Endocrine Society recommends using the Rotterdam criteria for diagnosing polycystic ovary syndrome and outlines first-line treatments, emphasizing hormonal contraceptives and lifestyle intervention.
52 citations
,
April 2008 in “Therapeutics and clinical risk management” This review covers the use of combined oral contraceptives, particularly drospirenone, for managing polycystic ovary syndrome and discusses related metabolic controversies without reporting new clinical results.
131 citations
,
August 2004 in “Best Practice & Research in Clinical Obstetrics & Gynaecology” This article reviews the complex pathophysiology of polycystic ovary syndrome, highlighting how genetic, hormonal, and environmental factors contribute to its diverse symptoms, and reports no new results.
76 citations
,
December 1997 in “Fertility and Sterility” This study found that spironolactone was significantly more effective than finasteride in reducing hirsutism scores over 9 months, despite more side effects occurring in the spironolactone group.
